Represented BarioSurg, Inc. in its merger of equals with EnteroMedics Inc., a publicly traded Delaware corporation (NASDAQ CM:ETRM), whereby Enteromedics acquired all of the equity of BarioSurg in exchange for the issuance of 1,380,684 shares of Enteromedics Common Stock, 1,000,181 shares of Enteromedics newly created Convertible Preferred Stock (convertible into approximately five million shares of Enteromedics Common Stock upon approval of Enteromedics’ stockholders) and $2 million in cash (less transaction expenses).
EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. BarioSurg, formerly known as Onciomed, Inc., is a privately held medical device company that has developed a proprietary long term, minimally invasive and reversible device, the Gastric Vest System™ (GVS), to treat obesity and glycemic control and dominate the multi-billion dollar obesity and diabetes market with this revolutionary and disruptive bariatric technology.
The Newport Beach-based team representing BarioSurg included Azad Virk, Marc Alcser, Jason Lee, and Matthew Brodsky. Kristin Larson advised on environmental and regulatory compliance matters.